Vaccination backslide
Listen to article
The Covid-19 pandemic caused a staggering 23 million children to miss out on basic childhood vaccines in 2020, which was the highest number recorded since 2009. According to a 2024 WHO report, global immunisation efforts were yet to fully recover, with vaccination rates for diseases like diphtheria, tetanus and measles remaining well below 2019 levels. And now, a new crisis threatens to derail progress almost as much as the pandemic did — the US aid funding cuts.
Trump's 'America First' policy, which introduced sizeable aid funding cuts, has already impacted numerous global humanitarian efforts. These include environmental protection and conservation work, aid for crisis impacted people, support for refugees of war-stricken countries, and, in Pakistan's case, HIV/AIDs prevention.
Outbreaks of infectious diseases including meningitis, measles and yellow fever, have been increasing globally at an alarming rate, but low and lower-middle income countries are taking substantial hits. This is especially concerning news for Pakistan, which has not yet achieved key goals of polio eradication and measles despite ongoing efforts for prevention and vaccination.
It is a saddening state of affairs that despite decades of progress in science and modern medicine, the world is still grappling with preventable diseases.
According to a joint release by WHO, Unicef and Gavi, the Vaccine Alliance, the US stands to risk similar outcomes in the childhood vaccination backslide — a crisis caused by the US funding cuts. This is not merely a health crisis, but a political and moral failure. The ripple effects of reduced funding threaten to undo years of collaborative progress for today's as well as future generations.
Pakistan now faces an even steeper climb towards disease prevention and immunisation efforts. With international funding no longer a sustainable and reliable option, the government must enact an action plan that prioritises domestic investment in public health infrastructure and outreach.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Recorder
a day ago
- Business Recorder
World No Tobacco Day: WHO, GoP join hands to deal with devastating economic & health impacts
ISLAMABAD: The government of Pakistan and the World Health Organization (WHO) have joined hands to jointly collaborate to deal with the devastating economic and health impacts of tobacco, which annually results in the deaths of 164,000 people and financially cause Rs700 billion or $2.5 billion losses to the country. The development came here on the occasion of World No Tobacco Day jointly organised by the WHO and the Ministry of National Health Services. The participants emphasised that all tobacco products on the market, without exception and regardless of the manufacturer, are extremely harmful to health and pose serious risks to people of all ages including children and teenagers. Speaking on the occasion, Additional Secretary Health Laeeq Ahmad said that Pakistan was a proud signatory to the World Health Organization Framework Convention on Tobacco Control, Pakistan remains firmly committed to implementing comprehensive, evidence-based measures to reduce tobacco use. He thanked all partners, including WHO, for their unwavering support. 'Together, let us work towards a tobacco-free Pakistan, a nation where our people can live, work, and thrive in an environment that values health, safety, and well-being,' He said that Pakistan in collaboration with WHO and other partners was committed to work together on urgent and sustainable measures to save lives. Measures include long-term increased taxation, advertising bans, regulation on plan packaging and product design to reduce appeal – especially to vulnerable populations such as children and teenagers, tobacco and nicotine-free public spaces, strict enforcement of tobacco control laws, and medical support for those who want to quit. Research has shown that measures such as tobacco taxation are effective in increasing revenues for the government while also reducing consumption, tobacco-related diseases, and pressure on health systems. Pakistan ratified the World Health Organization Framework Convention on Tobacco Control (WHO FCTC) in 2004, and WHO provides continuous technical support to the Ministry of National Health Services Regulations and Coordination and the Federal Board of Revenue in areas such as tobacco tax policy and track-and-trace implementation. WHO Deputy Representative in Pakistan Ellen Thom said, 'The 164,000 people dead to tobacco every year are not just numbers. They are workers with families. They are sons and daughters. They are also teenagers and children, who are particularly vulnerable and an easy target for the advertisement of the tobacco industry. Let us unmask the appeal. Tobacco is not a candy; it is a killer, and we need to protect our children, our families, and our communities.' Copyright Business Recorder, 2025
Express Tribune
a day ago
- Express Tribune
Covid resurges in India as active cases near 3,000
Listen to article India is witnessing a fresh surge in Covid-19 cases, with active infections nearing 3,000 nationwide, as Kerala emerges as the worst-hit state followed by Maharashtra and Delhi amid a sharp uptick in cases within just four days, NDTV reported. According to official data released by the Ministry of Health and Family Welfare, the country recorded 2,710 active cases as of May 30, up from 1,010 on May 26 — a nearly threefold increase. Kerala has reported the highest number of cases at 1,147, followed by Maharashtra with 424, and Delhi with 294. Gujarat has also recorded 223 cases. Other states reporting a notable number of infections include Tamil Nadu and Karnataka with 148 cases each, and West Bengal with 116. Rajasthan has recorded 51 cases, while Uttar Pradesh has reported 42. Smaller case numbers have been reported in Puducherry (25), Haryana (20), Andhra Pradesh (16), and Madhya Pradesh (10). Read more: CDC updates COVID vaccine guidance, keeps option open for healthy children Goa reported seven cases, whereas Odisha, Punjab, and Indian Illegallly Occupied Jammu and Kashmir (IIOJK) each reported four. Telangana, Arunachal Pradesh, and Chandigarh reported three cases each, while Mizoram and Assam recorded two cases each. Data from Bihar remains unavailable. At least seven deaths have been linked to the recent spike, though the cause of death remains under assessment in some instances. Among the fatalities, two occurred in Maharashtra and Delhi; both individuals reportedly had serious comorbidities. Except for one case in Punjab, all the deceased were senior citizens, officials said. Health authorities, however, have urged the public not to panic, stating that the current wave consists mostly of mild infections. Indian Council of Medical Research (ICMR) Director General Dr Rajiv Bahl said there is no cause for alarm but emphasised the need for continued vigilance. 'The public need not worry about this new variant of Covid-19. We just need to be vigilant,' he said earlier this week. 'We are not talking about enhanced precautions right now. But if someone is a cancer patient or has immunity problems, then we generally advise them to avoid any infection.' Also read: Covid-19 cases on the rise in India, with 2 new variants detected Genomic surveillance data from the Indian SARS-CoV-2 Genomics Consortium (INSACOG) shows that the most prevalent variant remains JN.1, accounting for 53 per cent of all recent samples. This is followed by the BA.2 variant (26%) and other Omicron sublineages (20%). The report also noted at least one confirmed case of the NB.1.8.1 variant, which is believed to be highly contagious, and four cases of the LF.7 variant — both currently classified by the World Health Organisation (WHO) as Variants Under Monitoring (VUMs). While these subvariants are not yet classified as Variants of Concern (VOCs), they are believed to be driving case spikes in parts of China and Asia.
Business Recorder
2 days ago
- Business Recorder
US FDA approves Moderna's next-generation COVID vaccine for adults 65 or older
The U.S. Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for everyone aged 65 and above, the company said on Saturday, the first endorsement since the regulator tightened requirements. The vaccine has also been approved for people aged 12 to 64 with at least one or more underlying risk factors defined by the Centers for Disease Control and Prevention, Moderna said in a statement. The company said it expects to have the vaccine, called mNEXSPIKE, available for the 2025-2026 respiratory virus season. 'The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19,' CEO Stephane Bancel said in the statement. The Department of Health and Human Services, under the leadership of long-time vaccine skeptic Robert F. Kennedy Jr., is tightening regulatory scrutiny on vaccines. The FDA said on May 20 it planned to require drugmakers to test their COVID booster shots against an inert placebo in healthy adults under 65 for approval, effectively limiting them to older adults and those at risk of developing severe illness. The Moderna vaccine can be stored in refrigerators rather than freezers, to offer longer shelf life and make distribution easier, especially in developing countries where supply-chain issues could hamper vaccination drives. The Centers for Disease Control and Prevention, which Kennedy also oversees, said on Thursday that COVID vaccines remain an option for healthy children when parents and doctors agree that it is needed, stopping short of Kennedy's announcement days earlier that the agency would remove the shots from its immunization schedule. The CDC announcement eases investor concern to some extent, analysts say, as it keeps the existing framework for older adults and at-risk people who generally seek out the shots. FDA leaders have said 100 million to 200 million Americans would still be eligible for annual shots. Moderna is betting on its newer messenger RNA vaccines as it grapples with waning demand for its original COVID vaccine Spikevax and lower-than-expected uptake of its respiratory syncytial virus vaccine. The approval for mNEXSPIKE was based on late-stage trial data, which showed the shot was not inferior in efficacy compared to Spikevax in individuals aged 12 years and older. The shot also showed superior efficacy compared to Spikevax in adults 18 years of age and older in the study. Kennedy has kickstarted a major overhaul of health departments, laying off thousands of employees to align with President Donald Trump's goal of dramatically shrinking the federal government. This has further ignited worries about potential disruptions to the regulatory review of treatments and vaccines. The CDC's outside panel of vaccine experts in April discussed recommending the booster shots only for populations at risk of severe COVID-19 for the upcoming immunization campaign. The FDA approved Novavax's COVID vaccine Nuvaxovid this month, limiting its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness. Conditions that constitute additional risk range from illnesses such as diabetes and heart disease to behaviors like physical inactivity and substance abuse, according to the CDC. While Moderna's shots, as well as Pfizer-BioNTech's Comirnaty, are mRNA-based, Novavax's vaccine is protein-based and takes longer to manufacture. Moderna this month withdrew an application seeking approval for its flu-and-COVID combination vaccine candidate to wait for efficacy data from a late-stage trial of its influenza shot.
